Drug Trial Radar · NCT06868290
Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Severe Active GPA or MPA
Last checked: Nov 20, 2026Latest source record: Sep 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
126
Planned (sponsor's estimate)
Start
Mar 13, 2025
Primary completion
Jun 7, 2029
Study completion May 24, 2030
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Mar 10, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy and safety of rapcabtagene autoleucel versus comparator in participants with severe active Granulomatosis with Polyangiitis (GPA) or Microscopic Polyangiitis (MPA)
Conditions
- ANCA Associated Vasculitis (AAV)
Interventions
Rapcabtagene autoleucelBiological
Single infusion of rapcabtagene autoleucel
Active ComparatorOther
Active comparator option as per protocol
GlucocorticoidsDrug
Concomitant glucocorticoids as per protocol
Primary outcomes
What the sponsor says the trial is designed to measure.
- Event-free survival (EFS)Time frame: From randomization until the occurrence of an EFS event, up to approx. 4 years after randomization
Locations
39 sites in 8 countries. Site status is shown where the registry gives one.
University Of Colorado
Aurora, Colorado
Mayo Clinic Jacksonville
Jacksonville, Florida
Northwestern University
Chicago, Illinois
Uni of Chi Medi Ctr Hema and Onco
Chicago, Illinois
Massachusetts General Hospital
Boston, Massachusetts
Michigan Med University of Michigan
Ann Arbor, Michigan
University of Minnesota
Minneapolis, Minnesota
Mayo Clinic Rochester
Rochester, Minnesota
Duke Clinical Research Institute
Durham, North Carolina
Oregon Health Sciences University
Portland, Oregon
University of Pennsylvania
Philadelphia, Pennsylvania
Baylor University Medical Center
Dallas, Texas
Houston Methodist Hospital
Houston, Texas
LDS Hospital
Salt Lake City, Utah
Novartis Investigative Site
São Paulo, Brazil
Novartis Investigative Site
Salvador, Estado de Bahia, Brazil
Novartis Investigative Site
Barretos, São Paulo, Brazil
Novartis Investigative Site
São Paulo, São Paulo, Brazil
Novartis Investigative Site
Haifa, Israel
Novartis Investigative Site
Ramat Gan, Israel
Novartis Investigative Site
Fukuoka, Japan
Novartis Investigative Site
Ishikawa, Japan
Novartis Investigative Site
Kyoto, Japan
Novartis Investigative Site
Chiba, Chiba, Japan
Novartis Investigative Site
Sapporo, Hokkaido, Japan
Novartis Investigative Site
Kobe, Hyōgo, Japan
Novartis Investigative Site
Sendai, Miyagi, Japan
Novartis Investigative Site
Suita, Osaka, Japan
Novartis Investigative Site
Bunkyo Ku, Tokyo, Japan
Novartis Investigative Site
Shinjuku-ku, Tokyo, Japan
Novartis Investigative Site
Riyadh, Saudi Arabia
Novartis Investigative Site
Singapore, Singapore
Novartis Investigative Site
Singapore, Singapore, Singapore
Novartis Investigative Site
Basel, Switzerland
Novartis Investigative Site
Bern, Switzerland
Novartis Investigative Site
Cambridge, United Kingdom
Novartis Investigative Site
Glasgow, United Kingdom
Novartis Investigative Site
London, United Kingdom
Novartis Investigative Site
Manchester, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.